These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22160877)

  • 1. Promises of PAR-1 inhibition in acute coronary syndrome.
    Leonardi S; Tricoci P; Mahaffey KW
    Curr Cardiol Rep; 2012 Feb; 14(1):32-9. PubMed ID: 22160877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
    Leonardi S; Tricoci P; Becker RC
    Adv Cardiol; 2012; 47():87-99. PubMed ID: 22906905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel anti-platelet agents: focus on thrombin receptor antagonists.
    de Souza Brito F; Tricoci P
    J Cardiovasc Transl Res; 2013 Jun; 6(3):415-24. PubMed ID: 23435863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.
    Leonardi S; Becker RC
    Handb Exp Pharmacol; 2012; (210):239-60. PubMed ID: 22918734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet protease-activated receptor antagonism in cardiovascular medicine.
    Wiisanen ME; Moliterno DJ
    Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
    White HD
    Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet thrombin receptor antagonism and atherothrombosis.
    Angiolillo DJ; Capodanno D; Goto S
    Eur Heart J; 2010 Jan; 31(1):17-28. PubMed ID: 19948715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
    Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
    Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
    Bhandari B; Mehta B
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.
    Leonardi S; Tricoci P; Becker RC
    Drugs; 2010 Oct; 70(14):1771-83. PubMed ID: 20836572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials.
    Capodanno D; Bhatt DL; Goto S; O'Donoghue ML; Moliterno DJ; Tamburino C; Angiolillo DJ
    J Thromb Haemost; 2012 Oct; 10(10):2006-15. PubMed ID: 22845871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
    Rollini F; Tello-Montoliu A; Angiolillo DJ
    Future Cardiol; 2012 Jul; 8(4):503-11. PubMed ID: 22871190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy: thrombin receptor antagonists.
    Tello-Montoliu A; Tomasello SD; Ueno M; Angiolillo DJ
    Br J Clin Pharmacol; 2011 Oct; 72(4):658-71. PubMed ID: 21906120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAR-1 antagonists: current state of evidence.
    Chatterjee S; Sharma A; Mukherjee D
    J Thromb Thrombolysis; 2013 Jan; 35(1):1-9. PubMed ID: 22644721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of vorapaxar for the prevention of atherothrombotic events.
    Wang A
    Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
    Tomasello SD; Angiolillo DJ; Goto S
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1557-67. PubMed ID: 20979570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
    TRA*CER Executive and Steering Committees
    Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
    Gurbel PA; Jeong YH; Tantry US
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.
    Goto S; Ogawa H; Takeuchi M; Flather MD; Bhatt DL;
    Eur Heart J; 2010 Nov; 31(21):2601-13. PubMed ID: 20805115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.